Esomeprazole Magnesium
Grundinformationen
- CAS
161973-10-0- Standard-SMILES
COc1ccc2[n-]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2]- InChIKey
KWORUUGOSLYAGD-YPPDDXJESA-N- Summenformel
- C34H36MgN6O6S2
- Durchschnittliche Molmasse
- 713,1 g/mol
Überblick
Esomeprazole magnesium is a magnesium salt resulting from the formal reaction of magnesium hydroxide with 2 mol eq. of esomeprazole. An inhibitor of gastric acid secretion, it is used for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. It contains an esomeprazole(1-).
Namen und Bezeichner
- Bevorzugter Name
- Esomeprazole Magnesium
- IUPAC
- magnesium bis(5-methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide)
- Englischer Name
- Esomeprazole magnesium
- Summenformel
- C34H36MgN6O6S2
- Molmasse
- 713.12
Namen und Synonyme
Esomeprazole magnesiumNexium 24hr925R0D7W1OCHEBI:50309Esomeprazole DrRefChem:55131Nexium 24HR ClearMinisEsomeprazole Magnesium DREsomeprazole Magnesium D/rDTXSID5044231DTXCID901618215Esomeprazole Magnesium Delayed-Release 20 mg mini
Weitere Namen anzeigen
(T-4)-bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN3]-magnesiumS-Form magnesium saltEsomeprazole magneslumEsomeprazole magnesium APIESOMEPRAZOLE MAGNESIUM/SODIUMESOMEPRAZOLE MAGNESIUM SAMPLENEXIUM(esomeprazolemagnesium)
Esomeprazole Magnesium Delayed-Release Capsules, 20 mgEsomeprazole Magnesium for delayed-release oral suspension161973-10-0R6DXU4WAY9Nexium(-)-Omeprazole magnesium(S)-Omeprazole magnesiummagnesium;5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
Datenbank-Bezeichner
- CAS
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 163 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 14
- Frei drehbare Bindungen
- 10
- Schwere Atome
- 49
- Formalladung
- 0
- Komplexität
- 453
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- Schmelzpunkt
- 169 °C · >169°C (dec.)
- Siedepunkt
- 600 ° · 600°
- storage temp.
- 2 · under inert gas (nitrogen or Argon) at 2-8°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- Farbe
- Off-White to Beige
- BCS Class
- 3 · 3
- Stabilität
- Hygroscopic
- InChI
- InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2
- InChIKey
- KWORUUGOSLYAGD-UHFFFAOYSA-N
- SMILES
- C(C1N=CC(C)=C(OC)C=1C)S1C2[N-]C3=CC(OC)=CC=C3N=2[Mg+2]2(O=S(CC3N=CC(C)=C(OC)C=3C)C3[N-]C4=CC(OC)=CC=C4N2=3)O=1
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 14.3% (1 of 7) of reports.
Warning
H302 (28.6%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 7 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (28.6%)
Sicherheitsdaten
- Alarmwort
- Warnung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
ESOMEPRAZOLE DR
Proton Pump Inhibitors [MoA]; Proton Pump Inhibitor [EPC]; Cytochrome P450 2C19 Inhibitors [MoA]
ESOMEPRAZOLE MAGNESIUM
Cytochrome P450 2C19 Inhibitors [MoA]; Proton Pump Inhibitors [MoA]; Proton Pump Inhibitor [EPC]
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, 20 MG
Proton Pump Inhibitors [MoA]; Proton Pump Inhibitor [EPC]; Cytochrome P450 2C19 Inhibitors [MoA]
MeSH Pharmacological Classification
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.
Anwendungen
VerwendenAntiulcerative
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter100 Anbieter
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
Zugehörige Reaktionen
3
Notizen zur Verbindung
Wird geladen…